Clinical Trial Update: Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating rituximab with or without Y-90 ibritumomab tiuxetan in untreated follicular lymphoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Mayo Clinic | Conditions: Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2023-07-18